Echiquier Health Impact For All I

Echiquier Health Impact For All focuses on investing in international healthcare companies that improve access to healthcare while upholding strong governance and sustainable practices. Its portfolio includes leading firms like Thermo Fisher, which is thriving in the growing lifescience sector, and Sandoz, a Swiss company preparing to launch a generic GLP-1 product in 2026. The fund also invests in Dynavox, a specialist in communication devices, and BoneSupport, a Swedish developer of innovative bone graft substitutes. Additionally, it actively manages its holdings by adjusting positions based on company performance, such as reducing its investment in Regeneron due to lower-than-expected sales.